|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|Neoadjuvant PD-1 blockade in resectable lung cancer|
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
|Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled†…|
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of clinical oncology 36 (7), 633, 2018
|Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy|
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
|Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer|
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
|Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer|
KC Arbour, L Mezquita, N Long, H Rizvi, E Auclin, A Ni, G MartŪnez-Bernal, ...
Journal of Clinical Oncology 36 (28), 2872-2878, 2018
|Serpins promote cancer cell survival and vascular co-option in brain metastasis|
M Valiente, AC Obenauf, X Jin, Q Chen, XHF Zhang, DJ Lee, JE Chaft, ...
Cell 156 (5), 1002-1016, 2014
|Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer|
L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, ...
Annals of Oncology 29 (6), 1437-1444, 2018
|Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study|
S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ...
The lancet oncology 17 (3), 299-308, 2016
|Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer|
JC Osorio, A Ni, JE Chaft, R Pollina, MK Kasler, D Stephens, C Rodriguez, ...
Annals of Oncology 28 (3), 583-589, 2017
|Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies|
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
|Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer|
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ...
Science translational medicine 5 (216), 216ra177-216ra177, 2013
|Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study|
MC Garassino, BC Cho, JH Kim, J MaziŤres, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
|Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas|
ME Arcila, JE Chaft, K Nafa, S Roy-Chowdhuri, C Lau, M Zaidinski, ...
Clinical cancer research 18 (18), 4910-4918, 2012
|Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint|
MD Hellmann, JE Chaft, WN William, V Rusch, KMW Pisters, N Kalhor, ...
The lancet oncology 15 (1), e42-e50, 2014
|EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics|
ME Arcila, K Nafa, JE Chaft, N Rekhtman, C Lau, BA Reva, MF Zakowski, ...
Molecular cancer therapeutics 12 (2), 220-229, 2013
|Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for†…|
JE Chaft, GR Oxnard, CS Sima, MG Kris, VA Miller, GJ Riely
Clinical cancer research 17 (19), 6298-6303, 2011
|Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small-cell lung cancer (BIRCH)|
S Peters, S Gettinger, ML Johnson, PA Jšnne, MC Garassino, D Christoph, ...
Journal of Clinical Oncology 35 (24), 2781, 2017
|Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)|
TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ...
Annals of Oncology 29 (8), 1853-1860, 2018
|Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care†…|
MG Kris, LE Gaspar, JE Chaft, EB Kennedy, CG Azzoli, PM Ellis, SH Lin, ...
J Clin Oncol 35 (25), 2960-2974, 2017